<DOC>
	<DOC>NCT02431260</DOC>
	<brief_summary>This is a study of INCB054329 given to patients with advanced malignancies that will be conducted in three treatment groups. Each treatment group will have two parts; a dose escalation (Part 1) and an expansion (Part 2).</brief_summary>
	<brief_title>An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<criteria>Confirmed diagnosis of advanced malignancy: Treatment Group A (TGA): Part 1:Any advanced solid tumor or lymphoma; Part 2: Histologically confirmed disease in specific tumor types Treatment Group B (TGB): Leukemia (Part 2 acute myeloid leukemia [AML] only), myelodysplastic syndrome (MDS), myelodysplastic /myeloproliferative neoplasms (MDS/MPN) and myelofibrosis (MF) Treatment Group C (TGC): Multiple myeloma Progressed following at least 1 line of prior therapy and there is no further approved therapy available that has been demonstrated to prolong survival (including subjects who are intolerant to the approved therapy) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Inadequate hematopoietic, liver, endocrine or renal function Receipt of anticancer medications or investigational drugs within the following interval before the first administration of study drug: &lt; 6 weeks for mitomycinC or nitrosoureas &lt; 28 days for any investigational agent (for any indication) &lt; 5 halflives for all other anticancer medications, or sponsor approval Prior radiotherapy within 2 weeks prior to first dose of study drug Untreated brain or central nervous system (CNS) metastases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>lymphoma</keyword>
	<keyword>BET bromodomain inhibitor</keyword>
	<keyword>BRD</keyword>
	<keyword>Diffuse large B-cell lymphoma (DLBCL)</keyword>
	<keyword>Burkitt's lymphoma</keyword>
	<keyword>c-MYC</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Pancreatic adenocarcinoma</keyword>
	<keyword>castration-resistant prostate cancer</keyword>
	<keyword>breast cancer</keyword>
	<keyword>NUT midline carcinoma</keyword>
	<keyword>leukemia</keyword>
	<keyword>acute myeloid leukemia (AML)</keyword>
	<keyword>atypical chronic myeloid leukemia (aCML)</keyword>
	<keyword>myelodysplastic syndrome (MDS)</keyword>
	<keyword>myeloproliferative neoplasms</keyword>
	<keyword>myelofibrosis (MF)</keyword>
	<keyword>multiple myeloma (MM)</keyword>
	<keyword>CMML</keyword>
	<keyword>MDS/MPN-U</keyword>
	<keyword>RARS-T</keyword>
</DOC>